Article

FDA’s New Risk Evaluation and Mitigation Strategy for Opioids

What you should know about the new REMS for opioids

Read more

The current class-wide Risk Evaluation and Mitigation Strategy (REMS) constitutes the most far-reaching REMS to date with implications for practitioners, hospital staff, pharmacists, patients, and analgesia drug developers.

Authors:

Chief Development Officer

Want to learn more about Worldwide Clinical Trials?